321 results on '"Socinski, M."'
Search Results
2. Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma: Topic: Medical Oncology: OA03.06
Catalog
Books, media, physical & digital resources
3. nab-Paclitaxel + carboplatin (nab-P/C) in advanced non-small cell lung cancer (NSCLC): outcomes in elderly patients (pts) with squamous (SCC) histology: 216PD
4. Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC): 1320_PR
5. 26MO Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
6. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses
7. P22.02 Combined Use of CYFRA 21-1, CA125 and CRP Predicts Survival of Metastatic NSCLC Patients With Stable Disease
8. MA07.02 Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150
9. Erlotinib in African Americans With Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses
10. LBA46 Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4)
11. Bevacizumab in the treatment of non-small-cell lung cancer
12. 1377P Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
13. 2032MO Correlation of safety and efficacy in atezolizumab therapy across indications
14. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
15. A benchmark study of cancer patient outcome in two Comprehensive Cancer Centers in the US and Germany: ID 461
16. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
17. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer
18. Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
19. Biomarker analysis in a phase III study of pemetrexed–carboplatin versus etoposide–carboplatin in chemonaive patients with extensive-stage small-cell lung cancer
20. 36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer
21. MA11.04 Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients
22. P90.03 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
23. Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC): V450
24. 375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC
25. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer
26. A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)
27. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
28. Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer
29. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity
30. IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)
31. MA13.05 Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study
32. OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC
33. Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
34. P1.16-04 Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC
35. OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D
36. P3.08-004 Phase I/II Trial of Nab-Paclitaxel or Paclitaxel Plus Carboplatin with Concurrent Radiation for Inoperable Stage IIIA/B NSCLC
37. MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study
38. OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma
39. LBA83 - Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
40. A Randomized Phase II Study of Carboplatin With Weekly or Every-3-Week Nanoparticle Albumin-Bound Paclitaxel (Abraxane) in Patients With Extensive-Stage Small Cell Lung Cancer
41. Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy
42. Hypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): Results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC)
43. A single-arm, open-label, phase 2 study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC)
44. Results of a Single-Institution Experience With Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer
45. Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) + carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2
46. NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
47. nab-paclitaxel (nab-P) + carboplatin (C) induction therapy in patients (Pts) with squamous (SCC) NSCLC: Interim quality of life (QoL) outcomes from the phase 3 ABOUND.sqm study
48. Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses
49. Tecemotide (L-BLP25) in unresectable stage III non-small cell lung cancer in the phase III start study : Further endpoint and exploratory biomarker results
50. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.